Overview

Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.

Status:
NOT_YET_RECRUITING

Trial end date:
2031-06-30

Target enrollment:

Participant gender:

Summary

This study tests a new treatment for men with high-risk prostate cancer who can't have surgery. The treatment combines three experimental drugs and radiation therapy. Researchers will track how well the treatment works and how safe it is. The study will last about five years.

Phase:

PHASE2

Details

Lead Sponsor:

ImmunityBio, Inc.

Treatments:

ALT-803
Androgen Antagonists